Vitamin d derivative tested as chemo booster for pancreatic cancer
NCT ID NCT04054362
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This small pilot study tested whether adding a vitamin D-like drug called paricalcitol to standard chemotherapy could help people with advanced pancreatic cancer that had stopped responding. 27 patients received chemotherapy first, then paricalcitol was added if their disease stabilized or worsened. The goal was to see if this combination could improve outcomes, but the study was very small and early-stage, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
paricalcitol (a form of vitamin D) added to chemotherapy (paclitaxel protein bound, gemcitabine, with or without cisplatin)
What this could lead to
If it works, this could point toward a way to improve chemotherapy response in advanced pancreatic cancer.
What could go wrong
This is a very small, early-phase pilot study with only 27 participants. It may not show clear benefit, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barts Health NHS Trust
London, London, Greater, EC1M 6BQ, United Kingdom